Biogen Idec receives 'notice of intention' from Icahn to nominate three more directors
US biopharmaceutical firm Biogen Idec says it has received notice from Icahn Partners and certain of its affiliates of their intention to nominate three individuals to its board of directors.
The three nominees - basically proposed by billionaire Carl Icahn in his third proxy fight with Biogen ' are: Eric Rowinsky, a former chief medical officer of ImClone Systems ( company acquired by Eli Lilly in 2008 for nearly $6 billion); Thomas Deuel, a former board member at ImClone; and Richard Young, a researcher at the Massachusetts Institute of Technology. Besides chief executive James Mullen, board member Bruce Ross is retiring. Also up for election are Brian Posner, former CEO of ClearBridge. Mr Icahn already has two board members, Alexander Denner and Richard Mulligan, who won seats in 2009.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze